Clinical Trials: World Market

2010-2025

Product Code VIS00135
Publication Date July 2010
Publisher Visiongain
Product Type Report
Pages 138
ISBN Number not applicable
Change currency
PDF £1,499.00 €1,805 $2,370 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Clinical Trials: World Market

2010-2025

Trends for outsourcing and off-shoring of clinical testing

The market for clinical trial services has been expanding rapidly, with impressive revenue growth and expansion of the sector in recent years.

Our new study shows how that sector will develop from 2010 onwards, with benefits to the pharma industry and clinical service providers. Clinical research organisations (CROs) are playing increasingly important roles in drug development worldwide, from conducting phase I trials to post-marketing studies.

Ageing populations, increasing prevalence of chronic diseases, growing demand for improved therapies and high growth of the pharmaceutical and biotechnology markets worldwide are driving the clinical trials sector and market. The globalisation of development programmes and the increasing complexity of trials - with regulatory developments - are heightening the need for larger trials and greater numbers of trials.

Many pharma companies are outsourcing clinical trials to gain cost savings/efficiencies, greater flexibility and specialist expertise. That trend will continue from 2010 onwards, our new study - Clinical Trials: World Market 2010-2025 - reveals. The emerging clinical trial destinations, including CEE countries, India and China, are achieving double-digit growth, our analyses show.

Our new report considers perspectives of sponsors and CROs for clinical trial outsourcing/off-shoring. We analyse the sector's strengths, weaknesses and financial prospects from 2010 to 2025 through quantitative and qualitative analyses. This report provides hard-to-find data on the current and future values of clinical trial spending and the CRO market, worldwide and regionally. We address global questions, such as: what proportion of the sector will be held by contract research organisations in future years? Our report also addresses regional questions. For example, how will India's share of global spending change between 2010 and 2025? Will the Central and Eastern European sector expand more rapidly than that of China? Our new report answers questions such as those, providing the information that you need.

Detailed analysis of the global clinical trials market

Clinical Trials: World Market 2010-2025 examines that sector critically, through a comprehensive review of information sources. We harness primary and secondary research. This report provides detailed sales forecasts, market share analyses and analyses of commercial drivers and restraints, including SWOT analysis. There are over 50 tables and figures and two full interviews with experts on the sector. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to benefit your work.

Why you should buy this report?

This report gives you the following benefits in particular:

  • You will receive spending forecasts for the global clinical trials sector from 2010 to 2025, covering in-house and outsourced spending respectively
  • You will receive spending/revenue forecasts for the clinical research outsourcing sector from 2010 to 2025, with comprehensive supporting information
  • You will receive forecasts for leading geographical segments for clinical research spending from 2010 to 2025 (North America, Western Europe, Central and Eastern Europe [CEE], India and China), including, growth rates and relative shares, with comprehensive discussions
  • You will explore the performance of leading clinical research providers and their commercial prospects
  • You will analyse the drivers, restraints, competition and opportunities influencing the clinical trials sector, especially the market for outsourced clinical services
  • You will receive expert views from our survey, including full interview transcripts
  • You will find out where the sector is heading - commercially and technologically - from 2010 onwards, with its prospects analysed and discussed.

This 2010 edition is re-written, with new analyses. It takes into account the changed economic environment, as well as developments in policy, technology and the market.

You can obtain this report today.

Our report is essential reading for everybody interested in pharma R&D and the clinical research market. With drives to increase R&D productivity and the development of many therapeutic classes, especially biotechnological drugs, the clinical trials market holds significant potential for revenue growth. Our study reveals prospects for outsourcing and off-shoring of clinical trials from 2010 onwards. You can stay ahead by ordering our new report today.

Contents

  • 1. Executive Summary
    • 1.1 This Report Provides Crucial, Hard-to-Find Clinical Trials Data
    • 1.2 Summary Points of This Report
    • 1.3 Aims, Scope and Format of Report
      • 1.3.1 Market Growth or Rising Costs?
      • 1.3.2 Chapter Outlines
    • 1.4 Research and Analysis Methods
  • 2. Introduction to Clinical Trials
    • 2.1 Costs of Clinical Trials
    • 2.2 Brief History of Clinical Trials
      • 2.2.1 The Nuremberg Code
      • 2.2.2 The Declaration of Helsinki
        • 2.2.2.1 The Declaration of Helsinki and Consent
        • 2.2.2.2 The Declaration of Helsinki and the Use of Placebo
        • 2.2.2.3 The Declaration of Helsinki and Individuals vs. Society
        • 2.2.2.4 The Declaration of Helsinki Replaced with Alternative Documents
      • 2.2.3 Council for International Organizations of Medical Sciences (CIOMS)
      • 2.2.4 Establishing International Standards for Good Clinical Practice
      • 2.2.5 The FDA's New Rules for Acceptable Foreign Clinical Studies
    • 2.3 Pre-Clinical Drug Studies
      • 2.3.1 Animal Models
      • 2.3.2 The FDA's Phase 0
    • 2.4 Standard Clinical Phases: Phase I-III Trials
      • 2.4.1 Phase I Trials
      • 2.4.2 Phase II Trials
      • 2.4.3 Phase III Trials
      • 2.4.4 Phase IV Trials: Post-Marketing Surveillance
    • 2.5 Basic Principles of Clinical Trial Design
      • 2.5.1 The Placebo Effect
      • 2.5.2 Inclusion Criteria and Exclusion Criteria
      • 2.5.3 Randomisation of Subjects
      • 2.5.4 Blinded Trials
      • 2.5.5 Endpoints
    • 2.6 Adaptive Clinical Trial Designs
      • 2.6.1 Adaptive Trials and Staging
      • 2.6.2 Adaptive Trials and Blending Phases
      • 2.6.3 Adaptive Trials, the FDA and the EMA
      • 2.6.4 Academia Setting the Standard?
    • 2.7 Clinical Trials and Genetic Tests
      • 2.7.1 Genetics and Micro-Arrays
      • 2.7.2 Toxicity Libraries
    • 2.8 Clinical Data Management Systems
      • 2.8.1 Clinical Trials Data Management Systems: Electronic Data Capture
      • 2.8.2 Hurdles Faced by Investigators in Implementing EDC
      • 2.8.3 Clinical Data Interchange Standards Consortium
  • 3. Global Clinical Trials Sector, 2009-2025
    • 3.1 Global Clinical Trials Sector in 2009
      • 3.1.1 Leading National Sectors for Clinical Trials, 2009
      • 3.1.2 Trials Overseen by In-House Clinical Development Teams
    • 3.2 Global Clinical Trials Spending Forecast, 2010-2025
      • 3.2.1 Fighting the Economic Crisis
      • 3.2.2 The Global Clinical Trials Sector: How Much Expansion is Possible?
      • 3.2.3 Sector Growth from 2020-2025
      • 3.2.4 Changing Shares in the Sector - Where Will be the Highest Gains?
    • 3.3 US and Canada: Spending Prospects
      • 3.3.1 North America Spending Share 2010 to 2025
    • 3.4 Western Europe: Spending Prospects
      • 3.4.1 Western Europe Spending Share 2010 to 2025
    • 3.5 Central and Eastern Europe (CEE): Spending Prospects
      • 3.5.1 CEE and Russia Share Rising Significantly
      • 3.5.2 Russia: Prospects from 2010
    • 3.6 India: The Fastest-Growing Outsourcing Destination?
      • 3.6.1 India's Spending Share 2010 to 2025
      • 3.6.2 India as a Case-Study
        • 3.6.2.1 Benefits and Concerns for India as a Location for Clinical
          • Research
        • 3.6.2.2 India Needs More Research Personnel
        • 3.6.2.3 Short- and Long-Term Personnel Goals
    • 3.7 China: Promising but Problematical
      • 3.7.1 China's Share Growing: Prospects from 2010 to 2025
    • 3.8 Other Emerging Clinical Trial Destinations
      • 3.8.1 Latin America
  • 4. Clinical Research Outsourcing Market, 2010-2025
    • 4.1 Contract/Clinical Research Organisations (CROs)
    • 4.2 Global CRO Market, 2009
      • 4.2.1 Value by Phase of Clinical Development, 2009
      • 4.2.2 Value by Sponsor Type, 2009
      • 4.2.3 Value by Leading Company, 2009
    • 4.3 Global CRO Market Forecast, 2010-2025
      • 4.3.1 Value of CROs Rising
      • 4.3.2 Increasing CRO Market Penetration from 2010 to 2025?
  • 5. Leading Companies in the Global CRO Market
    • 5.1 Quintiles
      • 5.1.1 Overview
      • 5.1.2 Recent Development and Growth Strategies
        • 5.1.2.1 Quintiles Increases Capacity in Africa
        • 5.1.2.2 Expanded Phase I Capacity
        • 5.1.2.3 Strategic Alliances
    • 5.2 Covance
      • 5.2.1 Overview
      • 5.2.2 Financial Performance
      • 5.2.3 Recent Development and Growth Strategies
        • 5.2.3.1 Preclinical and Phase I Sites
        • 5.2.3.2 Geographical Expansion into Emerging Markets
        • 5.2.3.3 Expansion into Biomarker and Drug Discovery Services
        • 5.2.3.4 Covance and Eli Lilly
    • 5.3 PPD
      • 5.3.1 Overview
      • 5.3.2 Financial Performance
      • 5.3.3 Recent Development and Growth Strategies
        • 5.3.3.1 Expansion in Emerging Regions
        • 5.3.3.2 Capturing Opportunities in Biologics and Vaccines Development
        • 5.3.3.3 Risk Sharing to Proprietary Drug Development
    • 5.4 Charles River Laboratories (CRL)
      • 5.4.1 Overview
      • 5.4.2 Financial Performance
      • 5.4.3 Recent Development and Growth Strategies
        • 5.4.3.1 Increasing Operational Efficiency in PCS Segment
    • 5.5 Parexel
      • 5.5.1 Overview
      • 5.5.2 Financial Performance
      • 5.5.3 Recent Development and Growth Strategies
        • 5.5.3.1 Expanding Capacity and Capabilities for Early-Phase Research
        • 5.5.3.2 Operational Developments in China
    • 5.6 ICON
      • 5.6.1 Overview
      • 5.6.2 Financial Performance
      • 5.6.3 Recent Development and Growth Strategies
        • 5.6.3.1 Extension of Partnership with Eli Lilly
        • 5.6.3.2 Expanding Capacity and Capabilities for Early-Phase Research
        • 5.6.3.3 Increasing Presence in Asia
    • 5.7 Kendle
      • 5.7.1 Overview
      • 5.7.2 Financial Performance
      • 5.7.3 Recent Development and Growth Strategies
        • 5.7.3.1 Kendle and DecisionLine
        • 5.7.3.2 Focus on High-Growth Regions
    • 5.8 PRA International
      • 5.8.1 Overview
      • 5.8.2 Financial Performance
      • 5.8.3 Recent Development and Growth Strategies
        • 5.8.3.1 Operational Expansion in Latin America and Asia
    • 5.9 PharmaNet Development Group (Formerly SFBC International Inc.)
      • 5.9.1 Overview
      • 5.9.2 Financial Performance
      • 5.9.3 Recent Development and Growth Strategies
        • 5.9.3.1 Expanding Geographical Footprint
    • 5.10 ReSearch Pharmaceutical Services (RPS)
      • 5.10.1 Overview
      • 5.10.2 Financial Performance
      • 5.10.3 Recent Development and Growth Strategies
        • 5.10.3.1 RPS Acquired Four CROs in Four Months
    • 5.11 MDS Pharma Services
    • 5.12 CMIC
    • 5.13 Omnicare Clinical Research
    • 5.14 The Clinical Trial Company (TCTC)
    • 5.15 Chiltern International, Ltd.
      • 5.15.1 Financial Performance
      • 5.15.2 Recent Development and Growth Strategies
        • 5.15.2.1 Expanding Presence in Latin America
    • 5.16 Averion International Corp.
      • 5.16.1 Averion Doubled Workforce by Acquiring Hesperion
    • 5.17 Veeda Clinical Research
    • 5.18 Synexus Clinical Research
    • 5.19 Clininvent/TCG Lifesciences
    • 5.20 Amarex
  • 6. Industry Trends from 2010
    • 6.1 Globalisation of Clinical Trials/Off-Shoring
      • 6.1.1 Emerging Regions Achieve Increase in Clinical Activity
      • 6.1.2 International Investigation Sites Registering for FDA Approval
      • 6.1.3 CROs Leveraging the Benefits of Emerging Markets
    • 6.2 Changing CRO Business Models
    • 6.3 Consolidation of the CRO Industry
    • 6.4 Technology Trends
      • 6.4.1 Patient-Centred Clinical Trials
    • 6.5 Biomarkers
  • 7. SWOT Analysis of the Clinical Trials Sector
    • 7.1 Strengths and Weaknesses of the Sector
    • 7.2 Opportunities
      • 7.2.1 The Effect of Thinner R&D Pipelines in the Pharma Industry
      • 7.2.2 Growing Demand for Biotech Drugs and Targeted Therapy
      • 7.2.3 Development of Biosimilars
      • 7.2.4 Adaptive Trials
      • 7.2.5 Outsourcing of New Services
        • 7.2.5.1 Drug Discovery
        • 7.2.5.2 Biomarkers
      • 7.2.6 Electronic Data Capture (EDC): Complementing Strategic Outsourcing
      • 7.2.7 Strains on the Blockbuster Model
    • 7.3 Threats
      • 7.3.1 Tightening Regulations
      • 7.3.2 Continuing Challenges for Emerging Outsourcing Markets
        • 7.3.2.1 Genetic/Ethnic Differences and their Relevance for
          • Pharmacotherapy
        • 7.3.2.2 Ethics for Outsourced Trials - Challenges and Developments
    • 7.4 Pharmaceutical Companies and CROs - Synergies and Challenges
      • 7.4.1 Increasing Competition: Potential Threat to CROs
    • 7.5 Perspectives on Benefits/Gains: Pharmaceutical Companies and CROs
  • 8. Opinion from Industry Experts
    • 8.1 Dr Fabio Thiers, Director, Global Clinical Trials Research Program,
      • MIT
      • 8.1.1 Future of Clinical Trials Market and Attractiveness of Emerging Destinations
      • 8.1.2 The Future of Outsourcing
      • 8.1.3 Outsourcing Opportunities by Phase of Development
      • 8.1.4 Outsourcing Opportunities by Therapeutic Area
      • 8.1.5 CRO Market Consolidation
      • 8.1.6 Regulations and Clinical Trials Market
      • 8.1.7 Industry Drivers and Restraints
    • 8.2 Dr Kevin Schulman, Associate Director, Duke Clinical Research
      • Institute; Director, Fuqua Health Sector Management Program, Duke
      • University
      • 8.2.1 Future of Clinical Trials Market and Attractiveness of Emerging
        • Destinations
      • 8.2.2 The Future of Off-Shoring
      • 8.2.3 The Future of Outsourcing
      • 8.2.4 Outsourcing Opportunities by Phase of Development
      • 8.2.5 Outsourcing Opportunities by Therapeutic Area
      • 8.2.6 CRO Market Consolidation
      • 8.2.7 Industry Drivers and Restraints
  • 9. Conclusions
    • 9.1 Global Clinical Trials Market
      • 9.1.1 Off-Shoring and Outsourcing
    • 9.2 The Growth of CROs
      • 9.2.1 Increasing Competition Among CROs
      • 9.2.2 Increased Regional Competition
    • 9.3 The Short-Term Future of the Sector
    • 9.4 The Longer-Term Future of the Sector
  • List of Tables
    • Table 2.1 Key Stages in History of Clinical Trials
    • Table 3.1 Clinical Trials Spending by Region ($m), 2009
    • Table 3.2 Clinical Trials Spending on In-House and CRO-Managed Trials ($bn), 2009
    • Table 3.3 Global and Regional Clinical Trials: Spending Forecasts ($m), 2010-2025
    • Table 3.4 US and Canada: Clinical Trials: Spending Forecast ($m), 2010-2025
    • Table 3.5 Costs and Benefits of Conducting Clinical Trials in North America, 2010
    • Table 3.6 Western Europe Clinical Trials: Spending Forecast ($m), 2010-2025
    • Table 3.7 Costs and Benefits of Conducting Clinical Trials in CEE Countries, 2010
    • Table 3.8 CEE Clinical Trials: Spending Forecast ($m), 2010-2025
    • Table 3.9 India Clinical Trials: Spending Forecast ($m), 2010-2025
    • Table 3.10 Benefits and Concerns for Clinical Trials in India, 2010
    • Table 3.11 China: Clinical Trials Spending Forecast ($m), 2010-2025
    • Table 3.12 Costs and Benefits of Conducting Clinical Trials in China, 2010
    • Table 4.1 Global CRO Market: Revenues by Phase of Clinical Development ($bn), 2009
    • Table 4.2 Global CRO Market: Revenues ($bn) by Sponsor Type, 2009
    • Table 4.3 Global CRO Market: Revenues ($bn) by Leading Company, 2009
    • Table 4.4 In-House and CRO-Managed Trials: Spending Forecasts ($bn), 2010-2025
    • Table 5.1 Other Companies in the CRO Market, 2010
    • Table 5.2 Covance Revenue ($m), 2008 and 2009
    • Table 5.3 PPD Revenue ($m), 2008 and 2009
    • Table 5.4 CRL Revenue ($m), 2008 and 2009
    • Table 5.5 Parexel Revenue ($m), 2008 and 2009
    • Table 5.6 Kendle Revenue ($m), 2008 and 2009
    • Table 6.1 Globalisation of Clinical Trials: Numbers by Country, 2005 and 2009
    • Table 6.2 Strategic Partnerships: CRO-Sponsor
    • Table 7.1 SWOT Analysis for the Clinical Trials Industry and Market, 2010-2025
    • Table 7.2 Benefits and Challenges to Outsourcing Host Countries, 2010
    • Table 7.3 Pharmaceutical Companies' and CROs' Perspectives on Costs and Threats, 2010
    • Table 7.4 Pharmaceutical Companies' and CROs' Perspectives on Benefits, 2010
  • List of Figures
    • Figure 2.1 Clinical Trial Phases
    • Figure 3.1 Clinical Trials: Regional Shares (%), 2009
    • Figure 3.2 Global Clinical Trials: Spending Forecast ($bn), 2010-2025
    • Figure 3.3 Clinical Trials: Regional Shares (%), 2010
    • Figure 3.4 Clinical Trials: Regional Shares (%), 2015
    • Figure 3.5 Clinical Trials: Regional Shares (%), 2020
    • Figure 3.6 Clinical Trials: Regional Shares (%), 2025
    • Figure 3.7 US and Canada: Clinical Trial Spending ($bn) and Share (%) Forecasts, 2010-2025
    • Figure 3.8 Western Europe: Clinical Trial Spending ($bn) and Share (%) Forecasts, 2010-2025
    • Figure 3.9 CEE Countries: Clinical Trial Spending ($bn) and Share (%) Forecasts, 2010-2025
    • Figure 3.10 India: Clinical Trial Spending ($bn) and Share (%) Forecasts, 2010-2025
    • Figure 3.11 China: Clinical Trial Spending ($bn) and Share (%) Forecasts, 2010-2025
    • Figure 4.1 Global CRO Market Shares (%) by Phase of Development, 2009
    • Figure 4.2 Global CRO Market Shares (%) by Sponsor Type, 2009
    • Figure 4.3 Global CRO Market Shares (%) by Leading Players, 2009
    • Figure 4.4 CRO Market: Revenue ($bn) Forecast, 2010-2025
    • Figure 4.5 CRO Market: Share (%) Forecast, 2010-2025
    • Figure 5.1 Covance Revenue Share (%) by Segment, 2009
    • Figure 5.2 PPD Revenue Share (%) by Segment, 2009
    • Figure 5.3 CRL Revenue Share (%) by Segment, 2009
    • Figure 5.4 Parexel Revenue Share (%) by Segment, 2009
    • Figure 5.5 ICON Revenue Share (%) by Geographical Region, 2009
    • Figure 5.6 Kendle Revenue Share (%) by Segment, 2009
    • Figure 5.7 Kendle Revenue Share (%) by Geographical Region, 2009
  • Companies Listed
    • AbC.R.O. Inc.
    • Almac
    • Altiora
    • Amarex
    • Amgen
    • Anapharm Clinics
    • Anapharm Europe
    • Anapharm Laboratories
    • Apollo Hospitals Group
    • Aptuit
    • Argenta Discovery
    • Arkios BioDevelopment International
    • Arrowhead Electronic Healthcare
    • Assistek
    • Association for the Accreditation of Human Research Protection Programs
    • (AAHRPP)
    • AstraZeneca
    • Averion International Corp.
    • BioClinica
    • BioDuro LLC
    • BioFocus
    • Bio-Kinetic Europe Ltd.
    • BMS
    • C&R Research
    • Celerion
    • Cenduit
    • Center for Drug Evaluation and Research (subsidiary of the US FDA)
    • Cerebricon Ltd.
    • Certara
    • Charles River Laboratories (CRL)
    • Chembiotek
    • Chiltern International Limited
    • ChinaGate
    • Clinical Data Interchange Standards Consortium (CDISC)
    • Clininvent
    • CMIC
    • Committee for Medicinal Products for Human Use (CHMP)
    • Contract Research Organisation Union of China (CROU)
    • Council for International Organizations of Medical Sciences (CIOMS)
    • Covance
    • CRF Health
    • CRS Clinical Research Services Andernach GmbH
    • DATATRAK
    • DecisionLine Clinical Research Corporation
    • DreamCIS
    • Duke Clinical Research Institute
    • Duke University
    • Eisai Co.
    • Electronic Healthcare
    • Eli Lilly
    • ERT
    • etrials
    • European Medicines Agency (EMA, EMEA)
    • European Union (EU)
    • Excel PharmaStudies Inc.
    • Exco InTouch
    • Food and Drug Administration (US FDA)
    • Forenap Groupe
    • Furiex Pharmaceuticals, Inc
    • Galapagos N.V.
    • Genentech
    • Genstar Capital, LLC
    • Genzyme
    • GlaxoSmithKline (GSK)
    • GVK Biosciences
    • Hammersmith Medicines Research (HMR)
    • Harlan
    • Harrison Clinical Research
    • Hesperion
    • HungaroTrials Ltd.
    • i3 Research
    • ICON PLC
    • Imclone
    • INC Research
    • Infociencia S.L.
    • InforSense Ltd.
    • Institute for Medical Research Management and Biometrics (IMEREM)
    • International Conference on Harmonisation (ICH)
    • Intrials Research Clinical
    • inVentiv Clinical Solutions, LLC
    • Invivodata
    • ITR Laboratories Canada Inc.
    • JLL Partners
    • Johnson & Johnson
    • Kendle
    • LAB Research Inc.
    • LabVantage
    • LSK Global Pharma Services
    • Magen BioSciences
    • Massachusetts Institute of Technology (MIT)
    • MDS Inc.
    • MDS Pharma Services
    • Medpace Inc.
    • Medrio
    • Merck & Co.
    • National Institutes of Health (NIH)
    • Novartis
    • Novella Clinical
    • Novo Nordisk
    • Novotech (Australia) Pty Limited
    • Omnicare Clinical Research
    • Omnicare Inc.
    • Oncopartners
    • Otsuka
    • Paramax International (Beijing) Inc.
    • Parexel
    • Perceptive Informatics
    • Pfizer
    • Pharmaceutical Product Development, Inc. (PPD)
    • PharmaNet Development Group
    • Pharmstandard (Russia)
    • Pharsight Corporation
    • Phase Forward
    • PHT Corporation
    • Piedmont Research Center (PRC)
    • PRA International
    • Premier Research Group
    • Prologue Research
    • Proteome Sciences
    • Qualia Clinical Services, Inc.
    • Quintiles
    • ReSearch Pharmaceutical Services (RPS)
    • Ricerca Biosciences LLC
    • Roche
    • Rules-Based Medicine, Inc. (RBM)
    • Securities and Exchange Commission (SEC)
    • Servier
    • SFBC International, Inc.
    • SGS
    • ShangPharma
    • SIOGEN Biotech
    • SIRO Clinpharm
    • Standard & Poor's
    • Symfo
    • Synchron Research Services Ltd.
    • Synexus Clinical Research plc
    • Syngene
    • Takeda
    • Target Health Inc.
    • Taylor Technology
    • TCG Lifesciences (TCGLS)
    • TGA Sciences Inc.
    • The Clinical Trial Company (TCTC)
    • Therapharm Recherches
    • Thermo Fisher Scientific
    • Thywill LatAm Solutions
    • Tigermed Consulting
    • Tripos International
    • Tufts Center for the Study of Drug Development (Tufts CSDD)
    • United BioSource
    • United Nations Educational, Scientific and Cultural Organization
    • (UNESCO)
    • Veeda Clinical Research
    • Veeda Laboratories Ltd.
    • Vigiun
    • World Health Organization (WHO)
    • World Medical Assembly
    • WuXi PharmaTech